Updated and Expanded List of COVID Grants Across Multiple Institutes

Updated June 6, 2020

By ScienceDocs COVID grant writer Dr. Bilello

NIH Funding Opportunities Specific to COVID grants

https://grants.nih.gov/grants/natural_disasters/corona-virus.htm

NIAID

Notice of Intent to Publish a Funding Opportunity Announcement for Digital healthcare interventions to address the secondary health effects related to social, behavioral, and economic impact of COVID-19 (R01 – Clinical Trial Optional)  

https://grants.nih.gov/grants/guide/notice-files/not-mh-20-058.html

Notice Number: NOT-MH-20-058   INCLUDES MANY OTHER INSTITUTES

Release Date: June 04, 2020

Estimated Publication Date of Funding Opportunity Announcement: June 20, 2020

First Estimated Application Due Date: July 20, 2020

Earliest Estimated Award Date: April 20, 2021

Earliest Estimated Start Date: April 20, 2021

Purpose

The National Institute of Mental Health (NIMH) with other ICs are issuing this Notice of Intent to Publish a Funding Opportunity Announcement to promote new initiatives that will solicit applications to support research to determine the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), wearable devices] to address secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic, particularly among populations who experience health disparities and vulnerable populations.

This FOA will utilize the R01 activity code and academic researchers will be required to partner with digital health developers and/or existing well-established digital health delivery platforms to prepare and submit applications. This notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications. Details of the planned FOAs are provided below.

Notice of Intent to Publish Funding Opportunity Announcements for the RADx-UP Initiatives

Notice Number: NOT-OD-20-112 INCLUDES MANY OTHER INSTITUTES

 https://grants.nih.gov/grants/guide/notice-files/not-od-20-112.html

Key Dates
Release Date: May 29, 2020
Estimated Publication Date of Funding Opportunity Announcement: June 8, 2020
First Estimated Application Due Date: July 2020
Earliest Estimated Award Date: September 2020
Earliest Estimated Start Date:August 2020

The goal of RADx-UP is to reduce COVID-19 associated morbidity and mortality disparities for those vulnerable and underserved populations that are disproportionately affected by, have the highest infection rates of, and/or are most at risk for adverse outcomes from contracting the virus. This Notice encourages researchers to leverage partnerships with key stakeholders to conduct community-engaged research to understand COVID-19 disparities and to increase access and effectiveness of diagnostic testing interventions among underserved COVID-19 medically and/or socially vulnerable populations.

Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-AI-20-051

Release Date: May 19, 2020

First Available Due Date:  June 16, 2020

Expiration Date:    September 08, 2021

Related Announcements for COVID grants

PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-19-272 PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
PA-19-270 PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

NOTE This NOSI replaces NOT-AI-20-031, which was expired following the release of two FOAs that provide an expedited funding mechanism for research on SARS-CoV-2 and COVID-19 using the R01 and R21 funding mechanisms. Applicants interested in pursuing NIH funding support utilizing either of these mechanisms is encouraged to consider the following funding opportunities:

• Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed): https://grants.nih.gov/grants/guide/pa-files/PAR-20-178.html
• Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed): https://grants.nih.gov/grants/guide/pa-files/PAR-20-177.html

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-EB-20-006
Release Date: April 10, 2020
First Available Due Date: April 05, 2020
Expiration Date: March 31, 2021

Related Announcements

PA-19-270 – PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
PA-19-272 – PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
PA-18-631 – NIBIB Exploratory Clinical Trials for Small Businesses ([R44] Clinical Trial Required)

Rapid Acceleration of Diagnostics (RADx)

https://www.poctrn.org/radx

Description: NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to  clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including, commercialization and product distribution. RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches.

Topics: SARS-CoV-2 diagnostic testing technologies in two stages:

• Early stage: transformative innovations based on novel testing strategies that have potential for major scale up
• Advanced stage: modification and optimization of existing SARS-CoV-2 testing approaches, including clinical laboratory tests, that can dramatically increase testing capacity

Due Dates: Rolling
Budget: Not specified

Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)

Notice Number: NOT-EB-20-007

https://grants.nih.gov/grants/guide/notice-files/NOT-EB-20-007.html

Release Date: April 10, 2020
First Available Due Date : June 05, 2020
Expiration Date: March 31, 2021

Related Announcements

PA-19-056 – NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-18-418 – NIBIB Research Project Grant (R01 Clinical Trial Required)

PAR-18-530 – Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 – Clinical Trial Optional)

PAR-20-155 – Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)

PAR-20-084 – NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

PAR-18-433 – NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)

PA-19-052 – NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

NOT-OD-20-091 – UPDATE: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19)

Purpose:  The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years

National Cancer Institute: DOVID Grants

Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-039.html

Description: The NCI has announced the availability of grant funding through the cooperative agreement mechanism U01 for SARS-CoV-2 research projects that will be part of a Serological Sciences Network (SeroNet).

Topics:

• Identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection
• Understanding the mechanisms driving the serological, humoral, and cellular immune responses
• Determining host, genetic, and environmental modifiers of the immune response
• Determining the serological correlates of disease pathogenesis and protection against future infection
• Defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing

Posted Date  June 05, 2020

Open Date (Earliest Submission Date) June 22, 2020

Application Due Date  July 22, 2020

Scientific Merit Review: August 2020

Advisory Council Review:  August 2020

Earliest Start Date: September 30, 2020

NCI intends to commit $6-8 Million in FY 2020 to fund five to 10 awards.

Budget: Restricted to $500,000 in direct costs at application

National Institute of Neurological Disorders and Stroke (NINDS): COVID Grants

NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

Notice Number: NOT-NS-20-051

https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-051.html

Release Date: April 30, 2020
First Available Due Date: May 01, 2020
Expiration Date: April 15, 2021

Related Announcements

NOT-NS-20-074 Notice of Change to Eligible Activity Codes for NOT-NS-20-051

PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)

PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

NOT-OD-20-026 New NIH “FORMS-F” Grant Application Forms and Instructions Coming for Due Dates on or after May 25, 2020

Issued by National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Alcohol Abuse and Alcoholism (NIAAA) – New participating organization as of 05/08/2020 for due dates on/after 05/08/2020

Description: NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Budget: $200,000 in direct costs

National Institute of Drug Abuse (NIDA)

NOSI: Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html

Notice Number: NOT-DA-20-047
Release Date: March 19, 2020
First Available Due Date: March 19, 2020 (Rolling after 3/19)
Expiration Date: March 31, 2021

Related Announcements

PA-18-935Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)
PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Budget: Maximum of $100,000 direct costs per year for 2 years.  Higher budgets may be considered with justification.

Other NIDA Funding 

https://www.drugabuse.gov/funding

National Center for Advancing Translational Sciences (NCATS): COVID Grants

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

Notice Number: NOT-TR-20-028
Release Date: April 23, 2020
First Available Due Date: May 04, 2020
Expiration Date: November 11, 2020

Related Announcements

PA-20-135 – Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)

PA-18-591 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Purpose

The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts.

Topics:

• Digital health platforms
• Planning of COVID-19 trials
• eConsent support
• Platforms for meta-analysis of COVID-19 trials
• Clinical data provision
• Clinical studies and trials of COVID-19 interventions
• Assessment of infectious or convalescent status

NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients as follows:

Older Funding Notices for COVID Grants:

NIH Guidance Related to COVID-19 Pandemic

https://www.youtube.com/watch?v=V5-Ry-2uGxs&feature=youtu.be

Proposal Submission & Award Management

• UPDATE: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19) – NOT-OD-20-091
• General Frequently Asked Questions (FAQs) – Proposal Submission and Award Management Related to COVID-19 – NOT-OD-20-083
• Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19 – NOT-OD-20-086

Human Subjects & Clinical Trials

• Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19 – NOT-OD-20-087
• FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic

Animal Welfare

• OLAW Webinar: Pandemic Contingency Planning and Its Impact on Animal Care – March 19, 2020 
• Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19 – NOT-OD-20-088

Peer Review

• Based on NIH Guidance on Travel and Meetings , in-person NIH peer review meetings are being held in alternate formats. Scientific review officers will be in contact with peer reviewers about these changes.

BARDA SPECIFIC FUNDING for COVID Grants

https://www.phe.gov/about/barda/Pages/default.aspx

https://beta.sam.gov/opp/e33b08d0e9e04e6faf2f84d5e25c1970/view?keywords=BARDA&sort=-relevance&index=&is_active=true&page=1

2020 NIAID Omnibus Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2020-1 – COVID-19 Proposals

BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat.  BARDA’s annual budget of $512 Million has been supplemented by an additional $3.5 billion through the recently passed Coronavirus Aid, Relief, and Economic Security (CARES) Act. 

The latest BARDA Broad Agency Announcement (BAA) is amendment 17 posted on June 3, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
• [NEW] AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms
• AOI 8.3 COVID-19 Vaccine
• AOI 9.2 COVID-19 Therapeutics
• AOI 10 Respiratory protective devices
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA suspended AOI 9.3 immunomodulators or therapeutics targeting lung repair, suspended AOI 9.5 Pre-exposure and post-exposure prophylaxis, suspended AOI 11 Ventilators, revised language for AOI 3 Antibacterials (submissions are placed in post COVID-19 review queue), added AOI 7.7.4, and revised language for AOI 9.2, 9.3, 9.5. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offeror should also complete the Submission Data Integration Table.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

DRIVe BARDA’s Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement

The Drive Business Model

Act to stimulate innovation through both non-dilutive funding and dilutive funding. In addition, through our DRIVe Accelerator Network, we will have teams forward deployed throughout the USA to identify promising solutions wherever innovation is happening. Together we are building out an ecosystem of restless innovation, driven by industry and the entrepreneurial community, to address our nation’s largest health security threats.

• Contract Opportunity Type: Solicitation (Updated)
• All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
• Updated Published Date: Jun 04, 2020 03:49 pm EDT
• Updated Date Offers Due: Feb 03, 2023 05:00 pm EST
• Updated Inactive Date: Feb 18, 2023

6/4/2020 – Amendment 001 to the EZ-BAA is now included as an attachment.  Amendment 001 revises Section C of the EZ-BAA.

Please also see Special Instructions 008 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 008, BARDA is revising topic #4.3 immediately, and closing topic #4.4 at 1700 HRS ET on 05 June 2020 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). 

Request a USG CoronaWatch Meeting

If you are interested in partnering with the federal government on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners!  The federal government established a single point of entry for product developers to submit their research on 2019 novel coronavirus medical countermeasures. Submit a brief description and supporting materials through our CoronaWatch Portal.

NSF FUNDING RELATED TO COVID Grants

https://www.nsf.gov/news/special_reports/coronavirus/

Research on Coronavirus (COVID-19)

• Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) — RAPID
  • Frequently Asked Questions (FAQs) regarding the NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-052)
• Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19) — RAPID
• Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19
• NSF Supporting Research to Address Coronavirus Disease blog

Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19

March 25, 2020

Dear Colleagues:

The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorateinvites US-based small businesses to submit Phase I proposals focused on the developmentand deployment of new technologies, products, processes, and services with the potential topositively impact the nation’s and world’s ability to respond to the COVID-19 crisis.

 Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. Interested proposers are invited to submit to the NSF Small Business Innovation Research(SBIR) and Small Business Technology Transfer (STTR) Phase I Program

Department of Defense (DoD) COVID Grants:

DoD SBIR

https://rt.cto.mil/rtl-small-business-resources/sbir-sttr/

DOD Instructions

• DOD SBIR 20.2 BAA (pdf)  Updated June 5, 2020
• DOD STTR 20.B BAA (pdf) Updated June 2, 2020 

**Due to unexpected circumstances, the Air Force will not participate in the DoD 20.2 SBIR/20.B STTR Broad Agency Announcements (BAAs) nor the Air Force X20.2 SBIR/X20.B Commercial Solutions Openings (CSOs). The Air Force will participate in the DoD 20.3 SBIR/ 20.C STTR BAAs and the Air Force X20.3 SBIR/X20.C STTR CSOs, scheduled for pre-release on 25 August 2020.**

Congressionally Directed Medical Research Programs

 COVID-19 FAQs for Grant Applicants and Recipients (Version 2, March 25, 2020)

The Defense Logistics Agency (DLA) implements, administers, and manages the SBIR/STTR Program as part of the Small Business Innovation Programs through DLA J68 Information Operations / Research, and Development (R&D) Division. Consult the program website at the following location: http://www.dla.mil/SmallBusiness/SmallBusinessInnovationPrograms for general information about the DLA SBIP Program and its mission.

Also See: https://www.dodsbirsttr.mil/submissions/login

The Defense Logistics Agency (DLA) has topics for Phase I, Phase II, and Direct-to-Phase II submissions to the DoD SBIR 20.2 Broad Agency Announcement that request novel approaches for the detection of and protection from emerging viral pandemics. Due date for DoD SBIR 20.2 is July 2, 2020

Topics:

• DLA202-D011 Novel Approaches for Detection of and Protection from Emerging Viral Pandemics (Ph I, II)
• DLA202-D013 Novel Approaches for Detection of and Protection from Emerging Viral Pandemics (Direct to Ph II)

Learn more about COVID Grant Writer Dr. Bilello